Kibo Energy PLC (Incorporated in
(Registration Number: 451931)
(External registration number: 2011/007371/10)
LEI Code: 635400WTCRIZB6TVGZ23
Share code on the JSE Limited: KBO
Share code on the AIM: KIBO
ISIN: IE00B97C0C31
('Kibo' or 'the Company')
Dated: 20 August 2024
Kibo Energy PLC ('Kibo' or the 'Company')
Kibo Subsidiary Announces Business Update
Kibo Energy PLC (AIM: KIBO; AltX: KBO), the renewable energy-focused development company, announces a business update by its subsidiary Mast Energy Developments PLC ('MED'), a
Further details can be found in the full MED RNS Announcement, which is available below and at med.energy.
_________________________
Dated: 20 August 2024
Mast Energy Developments PLC ('MED' or 'the Company')
Pyebridge 2nd Genset Overhaul Commences and Application for Increased CM Contract
Mast Energy Developments PLC is pleased to announce the official commencement of the 2nd genset overhaul, and application for an increased Capacity Market contract at its Pyebridge flexible power generation asset ("Pyebridge"). The details of the foregoing are set out below.
Pyebridge Key Highlights
· First refurbished genset achieving c.
· Pyebridge signed Engineering Works contract for 2nd genset's overhaul; and
· 2nd genset overhaul enables Pyebridge to apply for enhanced capacity CM contract.
Further to the Company's previous announcement dated 7 August 2024, following the successful completion of the refurbishment of the first of the Pyebridge site's 3x 2.7MW Jenbacher gensets (thus 8.1MW generation capacity in total), and the resulting first refurbished genset achieving c.
In addition to the expected enhanced revenue generation via Pyebridge's PPA with Statkraft, the overhaul of the 2nd genset enables, and it is expected that Pyebridge will apply for its next T-1 CM contract in the upcoming CM pre-qualification assessment window and subsequent bid auction for the 2025/2026 delivery year, at an enhanced generation capacity, which will result in increased contractual gross profit margin income received from that contract.
Once the work on the 2nd genset has been completed, Pyebridge will have 2x 2.7MW completely refurbished gensets operating and generating at optimum capacity and performance, which should have a direct positive impact regarding the site's PPA revenue generation accordingly. The plan remains to overhaul the then remaining 3rd genset in due course, in order to maximise full reliability, efficiency and revenue generating ability of the Pyebridge site in the most cost-efficient manner.
During the time that the work on the 2nd genset will be performed, it is expected that the site's first refurbished genset will remain operational and will largely continue to generate revenue via its PPA with Statkraft. Pyebridge will also keep receiving its current Capacity Market contract income from the government as previously announced.
The total costs for the above referred works on the 2nd genset's overhaul will be funded under the Project Finance agreement with RiverFort (please refer to previous announcement dated 28 February 2024 for further details of the Project Finance), with Pyebridge as the borrower. As such, the board of MED has agreed with RiverFort a 3rd Advance against the Project Finance agreement amounting to a gross total of
The Project Finance with RiverFort, has enabled the successful completion of the first genset's overhaul, as well the commencement of the 2nd genset's overhaul, and MED is appreciative of RiverFort's ongoing support as its asset-level strategic funding partner, in order to grow the business.
Pieter Krügel, MED CEO, commented: "We are pleased to have officially initiated the 2nd genset's overhaul, following the successful completion of the 1st genset's overhaul and its positive maiden performance results. It is expected that the completion of the 2nd genset's overhaul will not only see additional enhanced revenue generation via the Pyebridge site's PPA with Statkraft, but also enable the application for an enhanced CM contract which will further boost income.
"MED's funding partnership with RiverFort has been instrumental in enabling and fast-tracking the work programme at Pyebridge, which has already resulted in increased revenue generation sooner than expected. RiverFort's ongoing support to MED is invaluable and much appreciated.
"We are looking forward to updating the market with further progress across the board in due course."
ENDS
This announcement contains inside information for the purposes of the
For further information please visit www.med.energy or contact:
Pieter Krügel |
Mast Energy Developments PLC |
CEO |
|
Jon Belliss |
+44 (0)20 7399 9425 |
Novum Securities |
Corporate Broker |
_______________________
**ENDS**
For further information please visit www.kibo.energy or contact:
Cobus van der Merwe |
Kibo Energy PLC |
Chief Executive Officer |
|
James Biddle Roland Cornish |
+44 207 628 3396 |
Beaumont Cornish Limited |
Nominated Adviser |
Claire Noyce |
+44 20 3764 2341 |
Hybridan LLP |
Joint Broker |
James Sheehan |
+44 20 7048 9400 |
Global Investment Strategy |
Joint Broker |
Beaumont Cornish Limited ('Beaumont Cornish') is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.
20 August 2024
Corporate and Designated Adviser
River Group
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.